financetom
Business
financetom
/
Business
/
Celsius Top-Line Growth, Margins in Focus Ahead of Q3 Results, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Celsius Top-Line Growth, Margins in Focus Ahead of Q3 Results, UBS Says
Nov 4, 2025 12:07 PM

02:55 PM EST, 11/04/2025 (MT Newswires) -- Celsius (CELH) top-line growth will be the key focus when the company reports its Q3 results, with investors also increasingly attentive to its margin trajectory, UBS Securities said.

The brokerage said in a Monday note that the sentiment remains broadly positive heading into the print and expect continued strong fundamentals, projecting high-single-digit growth for the core Celsius brand and strong double-digit gains for Alani Nu in the quarter.

UBS forecast Q3 EPS of $0.27, about $0.01 below Visible Alpha consensus, and total company sales growth of 168.3%, slightly ahead of consensus at 164.8%. The brokerage also expects operating margin of 18.9%, above Street estimates of 18.1%, and gross margin of 51.3% versus the 51.2% consensus view.

The firm modeled a gross margin of 51.3% for the period, slightly above the 51.2% consensus estimate, reflecting Alani Nu's lower gross margin contribution, modest headwinds from higher aluminum prices, and about 20 basis points of dilution from the Rockstar brand.

Celsius is scheduled to report its Q3 results on Thursday.

UBS has a buy rating on Celsius with a $73 price target.

Price: 59.16, Change: -0.09, Percent Change: -0.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSR III Acquisition Says Terra Innovatum Signs Supply Deal With Conuar
GSR III Acquisition Says Terra Innovatum Signs Supply Deal With Conuar
Sep 16, 2025
09:14 AM EDT, 09/16/2025 (MT Newswires) -- GSR III Acquisition ( GSRT ) said Tuesday that Terra Innovatum has signed a memorandum of understanding with Argentina's Conuar to supply critical components for the production of Terra Innovatum's Solo micro-modular nuclear reactor. Under the agreement, Terra Innovatum and Conuar will launch pilot programs to evaluate the scope and pricing for Conuar...
Lantern Pharma Says Cancer Drug Shows Positive Safety, Early Efficacy in Phase 1 Trial
Lantern Pharma Says Cancer Drug Shows Positive Safety, Early Efficacy in Phase 1 Trial
Sep 16, 2025
09:15 AM EDT, 09/16/2025 (MT Newswires) -- Lantern Pharma ( LTRN ) said Tuesday a phase 1a trial evaluating its drug LP-184 as a potential treatment for advanced relapsed or refractory solid tumors met all primary endpoints and showed a strong safety profile, favorable pharmacokinetics, and early signs of antitumor activity. The company said no dose-limiting toxicities were reported in...
BRIEF-Strive Announces Acquisition Of Mstr True North Inc. Appoints Jeff Walton As Chief Risk Officer & CEO Of True North
BRIEF-Strive Announces Acquisition Of Mstr True North Inc. Appoints Jeff Walton As Chief Risk Officer & CEO Of True North
Sep 16, 2025
Sept 16 (Reuters) - Strive Inc ( ASST ): * STRIVE ANNOUNCES ACQUISITION OF MSTR TRUE NORTH INC. APPOINTS JEFF WALTON AS CHIEF RISK OFFICER & CEO OF TRUE NORTH Source text: Further company coverage: ...
Novo Nordisk eyes broader role for its obesity drugs from sleep apnea to knees
Novo Nordisk eyes broader role for its obesity drugs from sleep apnea to knees
Sep 16, 2025
* Novo seeking to reignite growth after Wegovy overtaken by rival * To test next-generation obesity drugs as broader treatments * Areas could include knee osteoarthritis and sleep apnea * Results of semaglutide Alzheimer's trial expected by year-end (Adds details from interview in paragraphs 5-7, 10) By Stine Jacobsen and Maggie Fick COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk, looking...
Copyright 2023-2026 - www.financetom.com All Rights Reserved